WEBCASTS
The Era of Biotech: How Biology Became Technology
First was the industrial revolution, then came the information era with the Internet; next up are genetics and biotechnology. New megatrends help steer the way the global economy develops. Should they steer your portfolio accordingly? In this upcoming webinar, WisdomTree and ETF Trends will look at innovation that is fueling healthcare industry and beyond.
SUMMARY
Tom Lydon, CEO of ETF Trends, will moderate a discussion on:
- An overview of the current developments in the biotechnology space
- An analysis of the companies that will be transformed by these developments
- A synopsis of WisdomTree's BioRevolution Fund strategy
NOT accepted for one hour of CFP/CIMA CE credit for live and on-demand attendees
CFA Institute members are encouraged to self-document their continuing professional development activities in their online CE tracker.
SPEAKERS
Jeremy Schwartz
Executive Vice President, Global Head of ResearchWisdomTree Asset Management
Jeremy Schwartz has served as our Executive Vice President, Global Head of Research since November 2018 and leads WisdomTree’s investment strategy team in the construction of WisdomTree’s equity indexes, quantitative active strategies and multi-asset model portfolios. Mr. Schwartz joined WisdomTree in May 2005 as a Senior Analyst, adding to his responsibilities in February 2007 as Deputy Director of Research and thereafter, from October 2008 to October 2018, as Director of Research. Prior to joining WisdomTree, he was head research assistant for Professor Jeremy Siegel and helped with the research and writing of Stocks for the Long Run and The Future for Investors. Mr. Schwartz also is co-author of the Financial Analysts Journal paper, What Happened to the Original Stocks in the S&P 500? He received his B.S. in Economics from The Wharton School of the University of Pennsylvania and hosts the Wharton Business Radio program Behind the Markets on SiriusXM 132. Mr. Schwartz is also a member of the CFA Society of Philadelphia.
Jamie Metzl
World Health Organization expert committee on human genome editing and AuthorJamie Metzl is a technology and healthcare futurist, geopolitical expert, novelist, social entrepreneur, media commentator, Senior Fellow of the Atlantic Council, Singularity University faculty member, and the Founder and Chair of the global social movement OneSharedWorld. In 2019, he was appointed to the World Health Organization expert advisory committee on human genome editing. Jamie previously served in the U.S. National Security Council, State Department, Senate Foreign Relations Committee, and as a Human Rights Officer for the United Nations in Cambodia. He serves on the Advisory Council to Walmart’s Future of Retail Policy Lab and has been an election monitor in Afghanistan and the Philippines and advised the government of North Korea on the establishment of Special Economic Zones.
Tom Lydon
CEOETF Trends
Disclaimer
By registering, you are certifying that you are a financial professional and agree to share your data with VettaFi and opt-in to receiving occasional communications about projects and events. The contents of this form are subject to VettaFi's Privacy Policy. You can unsubscribe at any time.
Important Disclosures
Before investing you should carefully consider the Fund’s investment objectives, risks, charges and expenses. This and other information is in the prospectus, a copy of which may be obtained by visiting the Fund’s website at www.wisdomtree.com. Please read the prospectus carefully before you invest.
There are risks associated with investing, including possible loss of principal. The Fund invests in BioRevolution companies, which are companies significantly transformed by advancements in genetics and biotechnology. BioRevolution companies face intense competition and potentially rapid product obsolescence. These companies may be adversely affected by the loss or impairment of intellectual property rights and other proprietary information or changes in government regulations or policies. Additionally, BioRevolution companies may be subject to risks associated with genetic analysis. The Fund invests in the securities included in, or representative of, its Index regardless of their investment merit and the Fund does not attempt to outperform its Index or take defensive positions in declining markets. The composition of the Index is governed by an Index Committee and the Index may not perform as intended. Please read the Fund’s prospectus for specific details regarding the Fund’s risk profile.
WisdomTree Funds are distributed by Foreside Fund Services, LLC, in the U.S. only.
Jeremy Schwartz is a registered representative of Foreside Fund Services, LLC.